Chad Moles, Author at Humane Genomics

The Science of Engineering Viruses

May 5, 2024 Chad Moles 0 Comment

Introduction Have you ever wondered how viruses are engineered in a lab setting? Although it may sound like complex wizardry, the process is quite approachable with a bit of molecular biology under your belt. This blog post aims to demystify the creation of viruses, making it accessible to anyone curious about the steps involved. Understanding Virus Structure Before diving into virus creation, it’s essential to understand what a virus consists of, in this case specifically lytic RNA viruses, as these…

Reflections from AACR: The evolving landscape of Oncolytic Viral Therapies

April 22, 2024 Chad Moles 0 Comment

We recently attended the American Association for Cancer Research (AACR) conference. It’s the largest cancer research gathering in the U.S., and we were thrilled to present our latest results and learn from peers. Here’s a snapshot of the current developments in oncolytic viral therapies (OVTs). The State of Oncolytic Viral Therapies Diverse Targets and Approaches:Presentations at AACR showed a strong interest in OVTs, featuring 39 oncolytic viruses from 23 companies and 11 research groups. These therapies aim to combat a…

Regulating viral replication using RNA aptazymes

August 28, 2023 Chad Moles 0 Comment

The biggest problem in cancer therapeutics is selectivity. Using oncolytic viral therapies, high selectivity can be achieved using the combination of selective infection and selective replication. Here, we want to address selective replication. For DNA viruses, this can be accomplished with promoters to control transcription and genome replication. However, for RNA viruses, this does not work. A potential solution to control replication for RNA viruses is the use of aptazymes. Aptazymes are self-cleaving units composed of a riboswitch and an aptamer….

Announcing our first publication

May 8, 2023 Chad Moles 1 comment

We are thrilled to announce the publication of Humane Genomics’ first article. We contributed a chapter to the International Review of Cell and Molecular Biology (IRCMB). This is a book series by Elsevier, as part of a special issue on Viral Vectors in Cancer Immunotherapy. Our review, titled “Rational selection of an ideal oncolytic virus to address current limitations in clinical translation,” offers valuable insights for investors, virologists, and newcomers to the field alike. In our article, we summarize the…

Scientific Data Supporting Our Proposal For COVID-19 Vaccine

March 17, 2020 Chad Moles 0 Comment

With a lot of countries taking more drastic measures and enforcing limited social contact (known as social distancing), we are left to ask, what is next? We believe it is possible to make a vaccine for COVID-19 that provides long lasting immunity. We also believe we can do this, fast. We recently shared our design here. Since then, we have found several papers that support our line of thinking. Included among these, an article by Liniger et al. that describes…

Proposal For Vaccine For COVID-19

March 12, 2020 Chad Moles 2 comments

Let me start by sharing, we are worried about the recent outbreak of COVID-19, also known as SARS-CoV-2 and 2019-nCoV. We feel deeply for all the people who are sick or have loved ones currently infected. We also see the impact on society. After the initial outbreak, like most of us, we continued with business as usual. We also hoped for and expected the rapid development of vaccines. (Read here about current efforts) At the present moment, however, we feel…

Introduction – Chad Moles

January 3, 2020 Chad Moles 0 Comment

The second in a series of Questions and Answers with the founders of Humane Genomics. Q: Tell me a bit about yourself. I’m a big science nerd. I’ve always been interested in the intersection of science and technology, and how it can advance humanity and healthcare. I also have a soft spot for animals, and have a dog, four cats, and 18 fish. Q: Why did you decide to become a founder of Humane Genomics? There are several reasons why…